Literature DB >> 2891686

Effects of minor tranquilizers and antidepressants on psychomotor performance.

A Smiley1.   

Abstract

Results of laboratory and epidemiologic studies have raised concern that psychotropic drugs may contribute to accidents. This article reviews studies of the effects of minor tranquilizer and antidepressant drugs on psychomotor performance. Data clearly demonstrate that the most commonly prescribed tranquilizer, diazepam, impairs many aspects of psychomotor performance for several hours after dosing, and there is no evidence that behavioral tolerance develops with continued drug use or that patients are differently affected than nonpatients. Lorazepam similarly impairs psychomotor performance. Other frequently prescribed benzodiazepine drugs have not been sufficiently examined to warrant conclusions about their psychomotor effects. A newly marketed nonbenzodiazepine anxiolytic, buspirone, has been shown to have few effects on performance skills. Only one antidepressant, amitriptyline, has been studied thoroughly enough to conclude that it impairs psychomotor performance. The few studies of other, newer antidepressants suggest they may cause less impairment; however, more research is needed to confirm this.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2891686

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  2 in total

1.  High dose benzodiazepines prolong reaction times in chronic users who have major depressive and/or anxiety disorders.

Authors:  Leonie Manthey; Fawzia van Loenen-Frösch; Erik J Giltay; Tineke van Veen; Klaske Glashouwer; Brenda W J H Penninx; Frans G Zitman
Journal:  Br J Clin Pharmacol       Date:  2014-03       Impact factor: 4.335

2.  Psychotropic drugs and driving: prevalence and types.

Authors:  Francisco Alonso; Cristina Esteban; Luis Montoro; Francisco Tortosa
Journal:  Ann Gen Psychiatry       Date:  2014-05-08       Impact factor: 3.455

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.